Feeds:
Posts
Comments

Archive for the ‘Oncology’ Category

Awesome Leukemia News

Yes, it’s still early – but research results like this make me do a happy dance!!!

_________

Impactiviti is the Pharmaceutical Connection Agency. As the eHarmony of sales/training/marketing, we help our pharma/biotech clients find optimal outsource vendors for training, eMarketing, social media, and more.

Learn more about our free services here

_________
Sign up for the Impactiviti Connection weekly e-newsletter (see sample), chock full of news and resources for pharmaceutical professional

Read Full Post »

*****

TODAY’S NEWS:

Prostate cancer drug treatment (Sanofi) approved on the fast track. But – a warning flag for S-A about possible Lantus/cancer link.

Bayer and OncoMed to co-develop oncology drugs in new agreement.

Novartis‘ blood cancer drug Tasigna gets approval for earlier use with CML.

RECOMMENDED

SocialRx – pharma social media resources. A page full of goodies, newly updated from us here at Impactiviti. Enjoy!

PLUS

Sex pills for women. Count me among the skeptics. And, medical flops of the decade (from Forbes).

JUST FOR FUN

Just where in the world is that South Africa place??

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.

TODAY’S NEWS:

As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just inTasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.

Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injectionmore

Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? - The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predictmore Also – huge sales force push for Prolia.

20% of high school students abuse prescription drugs. Wow – sobering.

RECOMMENDED

Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!

JUST FOR FUN

See-through animals. Ten of them. Amazing.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

Could low-dose Avandia be useful in preventing diabetes onset? This would be good news for GSK - GlaxoSmithKline Plc’s Avandia helped prevent the onset of diabetes when taken at a low dose with another drug, according to a company-sponsored study that suggests the regimen may help patients without raising heart attack risk. Half doses of Avandia and the therapy metformin, when combined, cut the risk of developing diabetes by two-thirds compared with placebo, Canadian researchers said..more

We’re in the gusher phase of the pre-ASCO press release flood. This sneak peek on BMS products is intriguing. More here – Four Scenarios for BMS.

Lying about data – people just don’t seem to learn. Sigh. And that goes for financial folks, politicians, climate scientists – it ain’t just pharma, folks!

Cephalon, Provigil and Nuvigil.

RECOMMENDED

Leadership Training. We’ve got the vendor/partners you need for this – field leaders or executive leadership level. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

New iPhone app released by Novartis subsidiary CibaVision. My “live” review while playing with it – mixed feelings. And, while we’re doing reviews – a north Jersey restaurant (Tabor Road Tavern) that blew me away.

JUST FOR FUN

Who needs PSA tests for prostate cancer when you have Fido? What’s interesting is that this is – amusingly – serious!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

We’re in the pre-ASCO oncology news build-up phase. Here’s a brief preview. And even more here.

Does HGH really help athletes? Interesting article – the last paragraph is the kicker.

Whistleblowers (J&J) get a payday. And, allegations about illegal sales practices by Roche with Tamiflu.

RECOMMENDED

eLearning. We know that space inside and out, and we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Karl Schmieder of MessagingLab interviews me about Impactiviti. Plus – the timing is never really “right,” is it? 29 and Counting.

JUST FOR FUN

If this doesn’t make you want to visit South America some day, nothing will!

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Hugely encouraging results for Novartis‘ new experimental (oral) MS treatment – Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients multiple sclerosis, cutting relapse rates by 62% in treatment-naïve patients and sustaining its effects for more than two years. Importantly, data from the two-year FREEDOMS study, presented at the American Academy of Neurology annual meeting, also showed that relapse rates were reduced by a significant 44% in patients who had previously been treated with other drugs for MS, highlighting the potential benefit of switching therapiesmore

Gilead starts late stage testing of “4-in-1″ HIV pill.

An interesting account of regulatory “unintended consequences.” How to make a cheap drug very expensive.

Cephalon hopes to gain more cheddar by adding some Swiss. Sorry – couldn’t resist…

Celgene: the new “big kid” on the block.

RECOMMENDED

Coaching Skills – The Impactiviti Partner Network is your resource if you’re looking to improve the coaching skills of your employees.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

An amusing patient health video made by J&J. Well worth 4 minutes of your time. The Appointment.

JUST FOR FUN

Oldie but goodie from The Onion – American to start charging fees to Non-passengers.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!

For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.

TODAY’S NEWS

Lilly in an Indy pullback.

Taking another look at medical uses for hallucinogens. Timothy Leary would be proud!

Byetta (once-weekly) and possible cancer risks. Frankly, I have a bit of problem with this sort of stuff. When you pump rats with mega-doses of just about anything, what do you expect? Eternal life?

If you need a Monday morning dose of super-sized, complex words in a cloud of oncology verbiage, this one’s for you. Otherwise, nothing to see here…

RECOMMENDED

Selling Skills – We can recommend best-in-class partners and programs for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Letting Go.

JUST FOR FUN

Visual treat – Steel Giants floating on a blanket of Fog.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers